D. E. Shaw & Co. Inc. Has $2.42 Million Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

D. E. Shaw & Co. Inc. decreased its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 15.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 421,594 shares of the biotechnology company's stock after selling 79,778 shares during the period. D. E. Shaw & Co. Inc. owned 1.98% of Enanta Pharmaceuticals worth $2,424,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. acquired a new position in Enanta Pharmaceuticals during the 4th quarter valued at about $26,000. Tower Research Capital LLC TRC lifted its holdings in Enanta Pharmaceuticals by 46.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock valued at $41,000 after buying an additional 2,274 shares during the period. Intech Investment Management LLC acquired a new position in Enanta Pharmaceuticals in the fourth quarter valued at approximately $58,000. Wells Fargo & Company MN boosted its stake in Enanta Pharmaceuticals by 69.6% in the fourth quarter. Wells Fargo & Company MN now owns 15,881 shares of the biotechnology company's stock valued at $91,000 after acquiring an additional 6,518 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in Enanta Pharmaceuticals during the 4th quarter worth $105,000. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Stock Up 1.0%

Shares of ENTA traded up $0.06 during trading hours on Monday, reaching $5.81. The stock had a trading volume of 67,695 shares, compared to its average volume of 286,008. The company has a market cap of $124.20 million, a P/E ratio of -1.17 and a beta of 0.81. Enanta Pharmaceuticals, Inc. has a 52 week low of $4.09 and a 52 week high of $17.24. The firm has a 50-day moving average of $5.41 and a 200 day moving average of $6.36.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.04) by ($0.02). The business had revenue of $14.93 million during the quarter, compared to analyst estimates of $15.96 million. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. As a group, equities analysts expect that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ENTA. HC Wainwright reissued a "buy" rating and issued a $18.00 price target on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. JMP Securities reiterated a "market outperform" rating and issued a $21.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. Finally, Wall Street Zen upgraded Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday, February 19th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $17.25.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.